PubMed · 14874017
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
K S LANDAUER. 1951. Recent developments in poliomyelitis.. https://pubmed.ncbi.nlm.nih.gov/14874017/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
We present an overview of our recent progress on spectroscopic trace gas detection for biomedical applications. The latest developments of cavity-enhanced spectroscopy as well as magnetic rotation spectroscopy lead to unprecedented sensitivity and specificity. The current detection limits of our laser spectroscopic approaches are in the picomolar to nanomolar range, depending on the molecular compound. The time resolution of the measurements is down to the sub-second range. This very high sensitivity and time resolution open up exciting perspectives for novel analytical tasks in biomedical research and clinical diagnosis.
BACKGROUND: The in vitro diagnostics directive of the European Union requires traceability to higher order reference measurement procedures and materials for analytes in assuring the result trueness and comparability of laboratory measurements. Manufacturers must ensure that the systems they market are calibrated against available reference systems. Validation of metrologically traceable calibrations is, however, required. METHODS: A commutable serum-based material was analyzed in three reference laboratories and target values for six enzymes (ALT, AST, CK, GGT, LD, amylase) were assigned using IFCC reference measurement procedures. 70 laboratories in Germany, Italy, and The Netherlands measured the same enzymes in the material using procedures from six commercial companies. A system for maximum allowable error was developed from the biological variation model and the results of the various procedures were tested on their compliance to trueness and between-laboratory and within-laboratory variations relative to the maximum allowable. RESULTS: For ALT results were relatively good. >95% of laboratories using systems from Dade, Olympus, Ortho and Roche are expected to comply traceability within the biologically derived limits, and 94% respectively 89% from Abbott and Beckman. For AST and GGT only Dade respectively Olympus fully complied. For CK all companies showed significant bias. Nevertheless >95% of laboratories applying Abbott, Beckman and Roche systems will comply. Finally, LD and amylase measurements require significant improvement. Some manufacturers continue to sell on the European market assays giving results which are not traceable to the internationally accepted reference systems. CONCLUSIONS: The traceability of enzyme measurements obtained with routine procedures to internationally accepted IFCC reference systems is not yet satisfactorily accomplished in clinical practice.